Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Welcome Email

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other, Topics

Lipfendra Label Analysis

Here is a brief preview of this blast: Recently, FDA approved Merck’s Lipfendra (enlicitide) as the first oral PCSK9i to treat adults with hypercholesterolemia, including those with HeFH (view label; view approval letter). With Merck poised to challenge established injectables such as Repatha, Praluent, and Leqvio, FENIX has conducted an in-depth Lipfendra label analysis, detailing how it compares to the market incumbents and how it may impact the LDL-C treatment landscape.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.